The persistent activation of signaling cascades results in dramatic consequences that include loss of cellular growth control and neoplastic transformation. We show here that phosphoinositide 3-kinase (PI 3-kinase) and its mediator Akt were constitutively activated in pancreatic cancer and that this might be due to the aberrant expression of their natural antagonist MMAC/PTEN. Indeed, our results show that MMAC/PTEN expression was either lost or significantly reduced in five of eight cell lines and in twelve of seventeen tumor specimens examined. That the poor expression of MMAC/PTEN in pancreatic cancer cells could be due to promoter methylation was indicated by methylation-specific PCR analysis. Our studies also indicated that PI 3-kinase targeted two important transcription factors in pancreatic cancer cells. The ability of constitutively activated NF-jB to induce gene expression and the stabilization of c-MYC protein by decreased phosphorylation of Thr58 were both dependent on PI 3-kinase activity. When pancreatic cancer cells were treated with a peptide antagonist of NF-jB nuclear translocation, or stably transfected with a dominant-negative mutant of MYC, their proliferation was markedly inhibited. Taken together, these data indicate that the aberrant expression of MMAC/PTEN contributes to the activation of the PI 3-kinase/Akt pathway and its transcription factor mediators in pancreatic cancer.
Introduction
The signaling mechanisms that might be responsible for the development and dissemination of pancreatic ductal adenocarcinoma, one of the leading causes of cancerrelated mortality in the Western world (Lillemoe, 1995; Evans et al., 1997) , are but incompletely understood. Genetic alterations of signaling molecules such as Ki-ras and the aberrant expression of ligand-receptor systems are thought to play a determinative role in the initiation and progression of this disease (Friess et al., 1999; Hilgers and Kern, 1999; Reddy, 2001) . Understanding this is one key to the design of new pancreatic cancer treatments.
Gain-of-function mutations in the Ki-ras gene occur in over 75% of pancreatic ductal carcinomas (Longnecker, 1999) , and the high mutation rate of this small G protein is a distinguishing feature of pancreatic tumors (Friess et al., 1999; Hilgers and Kern, 1999; Reddy, 2001) . The ability of Ras to trigger multiple cellular responses is dependent on downstream effectors such as phosphoinositide 3-kinase (PI 3-kinase) (RodriguezViciana et al., 1994; Campbell et al., 1998; Shields et al., 2000) . PI 3-kinase can be recruited and activated, however, not only by Ras but also by receptor and nonreceptor tyrosine kinases, many of which are commonly overexpressed in pancreatic tumors (Friess et al., 1999; Reddy, 2001) . PI 3-kinase signals may help cells proliferate and to evade programmed cell death when undergoing Ki-ras-and/or tyrosine kinase-induced transformation.
Whether activated by G proteins or tyrosine kinases, PI 3-kinase signals are transmitted to a protein kinase mediator known as Akt causing Akt to translocate to the plasma membrane where it undergoes phosphorylation on specific residues (Chan et al., 1999; Vanhaesebroeck and Alessi, 2000) . Both PI 3-kinase and Akt are proto-oncogenes (Staal et al., 1977; Chang et al., 1997) that play a critical role in human cancer (Chan et al., 1999) . Another important mediator is the MMAC/ PTEN phosphatase that dephosphorylates the phosphoinositide products of PI 3-kinase and functions as its natural antagonist (Maehama and Dixon, 1998; Cantley and Neel, 1999; Di Cristofano and Pandolfi, 2000) . It is logical therefore that MMAC/PTEN should function as a tumor suppressor gene and, indeed, it is widely mutated or deleted and its expression altered in precancerous lesions (Mutter et al., 2000) and advanced cancers (Li et al., 1997; Steck et al., 1997) . Furthermore, mice heterozygous for MMAC/PTEN are highly susceptible to tumors (Podsypanina et al., 1999) .
Whereas it is unclear as to how the PI 3-kinase pathway is activated and whether Ki-Ras, tyrosine kinases and MMAC/PTEN are involved, there is strong evidence that it plays a prominent role in pancreatic cancer. A recent study, for example, showed that when overexpressed in pancreatic cancer cells the Src tyrosine kinase induced an elevation in the insulin-like growth factor I receptor (IGF-IR) levels in a PI 3-kinase/Aktdependent manner and that treatment of Akt-transfected cells with IGF increased their invasiveness (Tanno et al., 2001) . When treated with the combination of gemcitabine and a PI 3-kinase inhibitor, several (Ng et al., 2000; Fahy et al., 2003) , if not all (Arlt et al., 2003) , normally resistant pancreatic cancer cell lines were sensitized to gemcitabine-induced apoptosis. Moreover, when PI 3-kinase was inhibited, the antitumor activity of gemcitabine was potentiated in orthotopic, human pancreatic cancer xenografts in immunodeficient mice (Ng et al., 2001) .
Other studies have shown that AKT2, one of three known Akt genes, is amplified in about 10% of pancreatic carcinomas (Cheng et al., 1996) . The growth and invasiveness of pancreatic cancer cells overexpressing AKT2 could be inhibited in a rat tracheal xenotransplant assay by antisense to AKT2 (Cheng et al., 1996) . These results suggest that AKT2 contributes to the malignant phenotype of a subset of human ductal pancreatic tumors. While they are known to occur in certain other cancers (Mills et al., 2001) , no alteration of other Akt or PI 3-kinase genes has been reported in pancreatic tumors. It is also noteworthy that no mutations or deletions have been reported in these tumors for the MMAC/PTEN gene either (Sakurada et al., 1997; Okami et al., 1998) . Whereas these and other important studies (Perugini et al., 2000; Bondar et al., 2002; Yao et al., 2002) indicated that the PI 3-kinase/Akt pathway has a crucial role in pancreatic cancer, the signaling mechanisms responsible for its 'constitutive' activation, and the transcription factors that serve as its mediators, have yet to be definitively identified.
We present evidence here to show that the PI 3-kinase signaling pathway is activated in pancreatic cancer, in part, through reduced MMAC/PTEN expression, that it regulates the transcription factors NF-kB and MYC, and that these two targets might be essential for its central role in the growth and survival of pancreatic cancer cells.
Results
The PI 3-kinase/Akt pathway is activated in pancreatic cancer cells
To examine its activity, we used specific antibodies to immunoprecipitate PI 3-kinase from different cell lines and performed lipid kinase assays with phosphatidylinositol as substrate. Antiphosphotyrosine (PY20) antibodies, the standard immunoprecipitant for activated PI 3-kinase, were almost as efficient as antibodies (a-p85) against the p85 regulatory subunit of PI 3-kinase ( Figure 1a) . Immunoprecipitation was specific, inasmuch as other antibodies such as those against MAP kinase did not precipitate any PI 3-kinase activity (data not shown).
Consistent with the presence of activated PI 3-kinase, its target protein kinase Akt was phosphorylated in all the pancreatic cancer cell lines examined (Figure 1b) . One of the physiological substrates of Akt is glycogen synthase kinase-3 (GSK-3) whose activity is repressed through Akt-mediated phosphorylation (van Weeren Figure 1 Constitutive activation of PI 3-kinase in pancreatic cancer cell lines. (a) Whole-cell extracts were prepared from various serum-starved cell lines for immunoprecipitation with either PY20 or anti-p85 PI 3-kinase antibodies. Immune complexes were assayed for PI 3-kinase activity with phosphatidylinositol as substrate. PIP (phosphoinositide 3-phosphate), which was resolved by thin-layer chromatography, migrated as indicated. (b) Wholecell extracts (100 mg) were prepared from serum-starved (16 h) pancreatic cancer cells and HEK 293 cells and subjected to Western blotting analysis of total Akt, GSK-3 and their phosphorylated forms (Ser 473 on Akt, Ser 21 on GSK-3a and Ser 9 on GSK-3b). IkBa was examined as loading control. Since all conditions were equal, this figure allows a direct comparison of the phosphorylated levels of Akt and GSK-3 between various pancreatic cancer cell lines , 1998) . It is therefore consistent that both GSK-3a and GSK-3b were also phosphorylated ( Figure 1b) . Akt phosphorylation was PI 3-kinase-dependent because it was sharply reduced in cells treated with the PI 3-kinase inhibitor LY294002 (Figure 2a) or that had been infected with MMAC/PTEN-expressing adenovirus (Figure 2b ).
MMAC/PTEN expression is reduced or lost in pancreatic ductal adenocarcinoma
Since the forced expression of wild-type MMAC/PTEN reduced the basal and serum-induced levels of Akt phosphorylation (Figure 2b ), the possibility arose that the endogenous gene was either inactive or improperly expressed. Because mutations in MMAC/PTEN are not present in pancreatic tumors and cell lines (Sakurada et al., 1997; Okami et al., 1998 ; data not shown), we investigated the possibility that MMAC/PTEN is instead expressed abnormally as in advanced human prostate cancer (Whang et al., 1998) . Paraffin sections from 17 pancreatic adenocarcinoma samples were subjected to immunohistochemical staining using specific antibodies against MMAC/PTEN. Residual normal adjacent tissues were present in 10 of the 17 samples, and ductal epithelial cells showed moderate to high staining for MMAC/PTEN (Figure 3a) . The smooth muscle cells in the blood vascular wall (Figure 3b ), intestinal wall and nerve fibers (Figure 3c ), which served as internal positive controls, showed high expression of the tumor suppressor gene. However, of the 17 pancreatic adenocarcinoma samples, four were negative for MMAC/PTEN immunostaining and were deemed to have lost expression of the gene (Figure 3d ). In three of these MMAC/PTEN-negative samples, residual normal pancreatic tissues had strong MMAC/PTEN expression. Of the remaining 17 samples, two showed weak staining and six had moderate expression levels (Figure 3e ). Strong immunostaining, comparable to that in normal tissues, was observed in only five of the specimens examined (Figure 3f ). Consistent with a reduction in MMAC/PTEN expression and in contrast to normal tissues (Figure 3g ), tumors ( Figure 3h ) had significantly higher levels of phosphorylated Akt. Interestingly, phosphorylated Akt was cytoplasmic in most, but not all, tumor cells in contrast to the normal tissue specimens where it appeared to be nuclear. However, because phosphorylated Akt was barely detectable in the normal tissues, it is unclear if its nuclear localization in a small number of cells is indicative of any essential difference between the normal and tumor specimens.
We next investigated if MMAC/PTEN was differentially expressed in pancreatic cancer cell lines as well. Immunoblotting analysis revealed that MMAC/PTEN expression was sharply lower in some cell lines such as MiaPaCa-2, BxPC-3 and Panc-28 than in others like Panc-1 and Capan-1 (Figure 3i ). Extracts were probed for two other proteins (actin and p110g PI 3-kinase) to confirm that the differences in MMAC/PTEN expression were not due to unequal loading. To determine if there was a correlation between its expression and the methylation status of its promoter, we analysed the MMAC/PTEN gene by methylation-specific PCR in five of these cell lines (Figure 3j ). The MMAC/PTEN promoter was indeed methylated in MiaPaCa-2 and BxPC-3 cells consistent with their low MMAC/PTEN levels. Furthermore, no methylation was detectable in Panc-1 and Capan-1, which expressed significantly higher levels of the tumor suppressor gene. Interestingly, the Panc-28 cell line was an exception because while it had low levels of MMAC/PTEN, the promoter did not appear to be methylated.
We then examined Akt phosphorylation (phosphoSer473) in cell lines and in nine of the 17 pancreatic tumor specimens to determine if a correlation could be drawn to the expression levels of MMAC/PTEN (Table 1) . Akt phosphorylation/activation was significantly lower in cell lines that expressed Pten at high levels (AsPC-1 and Capan-1) than in cell lines (BxPC-3, Panc-28 and Panc-48) that had little or no Pten. Furthermore, all three of the nine tumor specimens that were negative for MMAC/PTEN contained phosphorylated Akt consistent with the well-established inverse relationship between MMAC/PTEN expression and Akt activation. Of the other six samples, which , transcription factor NF-kB is also constitutively activated in pancreatic cancer (Wang et al., 1999) . Since we had previously identified a role for PI 3-kinase/Akt in NF-kB activation (Reddy et al., 1997; Reddy et al., 2000; Koul et al., 2001) , we investigated their relationship in pancreatic tumor tissues and cell lines. Using an antibody that recognizes IkB-free p65RelA/NF-kB (Wang et al., 1999) , we observed that IkB degradation and p65RelA nuclear localization did not appear to correlate with MMAC/ PTEN expression and Akt phosphorylation in pancreatic tumors (Table 1) .
Consistent with previous observations (Wang et al., 1999) , an NF-kB-dependent reporter gene was induced in pancreatic cancer cells (Table 2) , and could be inhibited by the specific IkB super-repressor. Induction of the reporter could, however, also be inhibited by a dominant-negative Akt mutant (Akt-AAA), MMAC/ PTEN and the dominant-negative mutants of PI Figure 3 MMAC/PTEN expression is absent or reduced in pancreatic ductal tumors. Sections from 17 pancreatic adenocarcinoma samples were subjected to immunohistochemical staining. Residual normal adjacent tissues were present in 10 of the 17 samples. In each of the 10 normal tissues, the pancreatic epithelial cells showed moderate to high staining for MMAC/PTEN (a). The smooth muscle cells in the blood vascular wall (b), intestinal wall and nerve fibers (c) showed moderate to high expression of the tumor suppressor gene. Of the 17 pancreatic adenocarcinoma samples, four were negative for MMAC/PTEN immunostaining (d), eight showed weak or moderate (e) expression levels of the tumor suppressor and five showed strong immunostaining (f). Normal (g) and tumor (h) tissues were also stained for phosphorylated Akt (Ser473). (i) MMAC/PTEN expression was evaluated in various pancreatic cancer cell lines and in HEK 293 cells by Western blotting analysis. These extracts were also probed for actin and p100g PI 3-kinase as loading controls (j) Genomic DNA was extracted from various pancreatic cancer cell lines, modified by sodium bisulfite and subjected to methylation-specific PCR analysis using primer sets specific for the methylated and unmethylated versions of MMAC/PTEN. For each cell line, the methylated and unmethylated PCR products were mixed and resolved by electrophoresis on a polyacrylamide gel Representative tumor specimens expressing b Pten at high, moderate/ weak or absent levels were analysed for the presence of activated c Akt (phospho-ser473) and d NF-kB (p65RelA that is not bound to IkB). A semiquantitative score for intensity was given to each sample relative to the staining observed for smooth muscle cells in blood vascular wall and in the intestinal wall: À, À/+, +, ++ PI 3-kinase/Akt in Pancreatic Cancer T Asano et al 3-kinase (p85aDN and p110aKR), indicating that both PI 3-kinase and Akt are essential for the function of constitutively activated NF-kB in pancreatic cancer cells (Table 2 ). The p85aDN was not as effective an inhibitor as Akt-AAA and p110KR for reasons that might be related to the relative expression of the endogenous p85a and p85b isoforms (data not shown). An activated form of Akt (gag-Akt), in contrast, induced reporter gene expression to about 4-5 times that observed with reporter alone. Thus, consistent with previous studies (e.g. Koul et al., 2001) , whereas PI 3-kinase/Akt is essential for the ability of NF-kB to transactivate genes, it may not be required for IkB degradation and RelA nuclear localization, the mechanisms that were investigated in our immunohistochemical analysis. A variety of signaling proteins are overexpressed in pancreatic cancer, including tyrosine kinases, transcription factors, cell cycle proteins and those that constitute ligand-receptor systems (Friess et al., 1999; Hilgers and Kern, 1999; Reddy, 2001; Shi et al., 2001; Schleger et al., 2002) . To identify other potential targets in pancreatic cancer cells, we investigated the effect of blocking PI 3-kinase on the expression of some of these signaling molecules. Of the proteins examined, LY294002 inhibited c-myc expression and implicated MYC as a PI 3-kinase target (Figure 4 and Table 3 ). Since the MAP kinase kinase (MEK) inhibitor PD98059 also inhibited c-myc expression (Figure 4 and Table 3), the PI 3-kinase and MAP kinase pathways appeared to cooperate in inducing or in stabilizing c-myc expression in most pancreatic cancer cell lines. The expression of EGF-R, TGF-bR1, Sp-1, cyclin D1, p27
Kip1 and Src did not appear to depend on PI 3-kinase activity for their expression in these cells (Figure 4) .
Since the mTOR kinase, an important PI 3-kinase mediator, is activated in pancreatic cancer cells (Grewe et al., 1999; Shah et al., 2001) , we examined the effect of its inhibitor rapamycin in an attempt to identify the mechanism by which MYC is regulated. Rapamycin did not affect MYC protein levels in any of the cell lines examined (Figure 4 and Table 3), and so PI 3-kinase could be regulating c-myc expression through other pathways such as via the suppression of GSK-3 activity.
Since the stabilization of exogenous MYC by adenovirally expressed Ras was recently shown in REF52 fibroblasts to be determined by the phosphorylation status of Thr58 (Sears et al., 2000) , we investigated if native MYC in pancreatic cancer cells was also regulated through a similar mechanism. Treatment of cells with LY294002 reduced endogenous MYC protein levels (Figure 5a ) as we observed earlier.
To determine if this reduction in MYC correlated with Thr58 phosphorylation, we investigated the effect of LY294002 but in the presence of a proteasome inhibitor (MG-132). Total MYC protein levels were sharply elevated in cells treated with MG-132 alone or in combination with LY294002 (Figure 5a ), suggesting After 24 h, whole-cell extracts were assayed for luciferase and b-galactosidase activities as described in Materials and methods. Luciferase activities were normalized to b-galactosidase and the controls were assigned a value of 100. Experiments were carried out in triplicate. Shown here are the averages and standard deviations. ND, not determined Figure 4 Identification of c-Myc as target of PI 3-kinase and MEK/ERK in pancreatic cancer cells. Serum-starved AsPC-1 and BxPC-3 cells were treated without or with LY294002 (PI 3-kinase inhibitor), rapamycin (mTOR inhibitor) or PD98059 (MEK inhibitor) for 6 h. Whole-cell extracts were prepared and used for Western blotting analysis with antibodies against the indicated proteins or phosphoproteins. To better visualize inhibitor effects, phosphorylated Akt bands from longer film exposure times are presented for the AsPC-1 cells. All panels shown here are derived from a single experiment for each cell line and so several proteins also serve as loading controls PI 3-kinase/Akt in Pancreatic Cancer T Asano et al that they had accumulated in response to decreased proteolysis and that a proteasome-mediated step might be required for the LY294002 effect. Interestingly, total MYC protein levels in cells treated with the combination of LY294002 and MG-132 were lower than in cells treated with MG-132 alone, suggesting that blocking the proteasome while effective did not completely block LY294002 action. Consistent with the increase in MYC protein, its phosphorylated form, which was barely detectable in untreated cells, was also elevated in MG-132 (with and without LY294002)-treated pancreatic cancer cells. Densitometric analysis indicated that the ratio of phosphorylated MYC to total MYC was significantly higher (4 : 1 for BxPC-3 and 1.8 : 1 for AsPC-1) in cells treated with MG-132 and LY294002 than in cells treated with MG-132 alone (1 : 1 for BxPC-3; 1 : 1 for AsPC-1). This would suggest that when PI 3-kinase was inhibited, MYC phosphorylation on Thr58 increased (Figure 5a ).
Because c-myc expression is also regulated transcriptionally, we next investigated if NF-kB was involved since it is constitutively activated in pancreatic cancer (Wang et al., 1999;  Table 1 ) and has recently been implicated in c-myc transcription (Grumont et al., 2002) . A MYC-responsive reporter gene (M4/luciferase) was strongly induced but was unaffected by overexpression of the IkB inhibitor (Figure 5b ). Since IkB inhibited an NF-kB-responsive reporter gene (Figure 5b ), these data indicate that NF-kB is not required for c-myc expression in pancreatic cancer cells.
PI 3-kinase, MYC and NF-kB are essential for the proliferation of pancreatic cancer cells
We evaluated the importance of the PI 3-kinase pathway to the proliferation of pancreatic cancer cells. Eight different pancreatic cancer cell lines (BxPC-3 shown here) were cultured in serum-containing medium in the absence or presence of LY294002 or PD98059. Whereas the cellular growth rates were significantly inhibited (Figure 6a ) by PD98059 (30-48% inhibition), they were even more sensitive to LY294002 treatment (55-90% inhibition). Interestingly, rapamycin, which did not inhibit c-myc expression, was significantly less effective than LY294002 in blocking the proliferation of pancreatic cancer cells (data not shown). Trypan blue exclusion assays and immunoblotting analysis of poly-ADP ribose polymerase (PARP) cleavage showed that greater than 90% of pancreatic cancer cells were viable even after 72 h of treatment with LY294002 (data not shown). However, when these cells were treated with Figure 5 PI 3-kinase regulates Thr58 phosphorylation and degradation of MYC. (a) Serum-starved BxPC-3 or AsPC-1 cells were incubated with LY294002 alone or in combination with the 26S proteasome inhibitor MG-132 for 6 h. Whole-cell extracts were probed for total or phosphorylated MYC and Akt. *The ratio of phosphorylated MYC to total MYC (identical film exposure times) was determined by densitometric analysis to be significantly higher (4 : 1 for BxPC-3 and 1.8 : 1 for AsPC-1) in cells treated with MG-132 and LY294002 than in cells treated with MG-132 alone (1 : 1 for both BxPC-3 and AsPC-1). (b) MYC-or NF-kB-responsive reporter gene was transfected into AsPC-1 cells with a control reporter (pCMV-LacZ) and with or without IkB. After 24 h, cell extracts were assayed for luciferase activity and all values were normalized to b-galactosidase activity PI 3-kinase/Akt in Pancreatic Cancer T Asano et al LY294002 in the absence of serum, they quickly underwent apoptosis, and fewer than 10% were viable beyond 48 h (data not shown).
Since MYC and NF-kB appear to be regulated by PI 3-kinase, we next investigated if these transcription factors were also required for cellular proliferation. Stable expression of a dominant-negative mutant of MYC (Mad-Myc), or treatment with a peptide antagonist of NF-kB nuclear translocation, significantly inhibited the proliferation of BxPC-3 cells (Figure 6b and c). The peptide antagonist (SN50) was employed at a lower concentration (25 mg/ml) than what was judged to be specific (Kolenko et al., 1999) , and was more effective in inhibiting proliferation than a control peptide (SN50M) that had the NF-kB nuclear localization site mutated.
Discussion
Our results indicate that the PI 3-kinase signaling pathway is activated in pancreatic cancer. The magnitude or duration of PI 3-kinase-initiated signals might be controlled not only by Ki-ras and tyrosine kinases but also by other proteins. They would include, for example, specific genes such as AKT2, which is amplified in about 10% of pancreatic tumors (Cheng et al., 1996) , and MMAC/PTEN, which is inactivated in a variety of cancers. Although mutations or deletions of MMAC/PTEN are not known to occur in pancreatic ductal cancer, our study demonstrates that its expression was impaired in a significant proportion of the tumor specimens and cell lines examined. That the functional impairment of MMAC/PTEN is associated with pancreatic cancer would be consistent with recent evidence that MMAC/PTEN is indeed expressed at lower levels in tumors than in normal tissues (Ebert et al., 2002) . We additionally used methylation-specific PCR analysis to demonstrate that promoter hypermethylation might be responsible for the reduced levels of MMAC/PTEN in pancreatic cancer cells. Since TGF-b1 overexpression reduced MMAC/PTEN expression in the pancreas of TGF-b1 transgenic mice, it might also be an important mechanism for regulating MMAC/PTEN function and in conferring growth advantage to pancreatic cancer cells (Ebert et al., 2002) . It is noteworthy in this context that although the MMAC/PTEN promoter did not appear to be methylated in Panc-28 cells, the gene was expressed at very low levels in that cell line. Whether, in fact, MMAC/PTEN expression was reduced in Panc-28 due to TGF-b1 overexpression remains to be investigated.
As may be expected, Akt phosphorylation/activation appeared to be inversely related to MMAC/PTEN expression in several pancreatic tumor specimens. Furthermore, phosphorylated Akt was significantly lower in cell lines that expressed Pten at high levels (AsPC-1 and Capan-1) than in cell lines (BxPC-3, Panc-28 and Panc-48) that had little or no Pten. A relationship between MMAC/PTEN expression and Akt activation was, however, not apparent in two tumor specimens and in the Panc-1, Panc-3 and MiaPaCa-2 cell lines. It is possible that the functional status of MMAC/PTEN (phosphorylation and interacting proteins) and the presence of other Akt regulators such as CTMP (Maira et al., 2001) would also influence the linear transmission of signals from PI 3-kinase to Akt in pancreatic cancer cells. The possibility that MMAC/ The proliferation of BxPC-3 cells stably transfected with empty vector or with a dominant-negative MYC mutant (Mad-Myc) was determined at various times by counting. (c) BxPC-3 cells were treated with 25 mg/ml of cell-permeable peptide antagonist (SN50) of NF-kB nuclear translocation or its mutated control (SN50M). The effect of these peptides on proliferation was determined by crystal violet staining PI 3-kinase/Akt in Pancreatic Cancer T Asano et al PTEN was inactive even when expressed is intriguing. While mutation and loss of expression are the predominant mechanisms for loss of MMAC/PTEN function, it is possible that any dysregulation of the mechanisms that insure its proper cellular localization or its binding to specific proteins (Wu et al., 2000) might also profoundly influence its function.
Our immunohistochemical data indicated that whether or not Akt was activated, NF-kB had dissociated from its IkB inhibitor and undergone nuclear translocation in pancreatic tumors. We also show, however, that MMAC/PTEN and dominantnegative Akt and PI 3-kinase mutants strongly inhibited NF-kB-dependent gene expression to suggest that the PI 3-kinase pathway was, in fact, required for NF-kB function in pancreatic cancer cells. This possibility is consistent with our earlier finding that while PI 3-kinase did not mediate cytokine-induced IkB degradation or NF-kB nuclear translocation, it was essential for the ability of NF-kB to transactivate robustly its target genes (Koul et al., 2001) . That PI 3-kinase is essential for NF-kB function in pancreatic cancer cells was also suggested by two recent studies that used LY294002 to study the mechanisms of BCL2 expression (Fahy et al., 2003) , and TNF-induced antitumor signaling (Shah et al., 2001) . Although the mechanism by which PI 3-kinase regulates NF-kB is not yet clear, it is likely to involve site-specific phosphorylation of the p65RelA/p50 subunits (Sizemore et al., 1999; Koul et al., 2001) . These studies have the potential to help us identify genes induced by PI 3-kinase via NF-kB that are central to the development and dissemination of pancreatic cancer.
A prominent role has been established for c-myc in tumorigenesis, and its constitutive expression is key to the genesis of many cancers (Dang et al., 1999) . However, the regulation of c-MYC synthesis and/or stabilization by PI 3-kinase and other signals are incompletely understood. It is also pertinent to note that while c-myc is amplified and overexpressed in primary and metastatic pancreatic ductal adenocarcinoma (Adsay et al., 1999; Nagy et al., 2001; Schleger et al., 2002) , its role and regulation in this cancer are poorly understood. Consistent with a recent report on the regulation of exogenous MYC by adenovirus-expressed Ras (Sears et al., 2000) , we show that the stability of native MYC in cancer cells is also dependent on PI 3-kinase-mediated signals. Specifically, our data indicate that PI 3-kinase stabilized MYC by inhibiting its phosphorylation on Thr58, a modification that marks it for proteasome-mediated degradation. Since Thr58 is a putative GSK-3-regulated site (Sears et al., 2000) , its increased phosphorylation in LY294002-treated cells is consistent with a derepression of GSK-3 activity that would occur when PI 3-kinase is inhibited. PI 3-kinase may not always be essential for MYC stability, however, because LY294002 did not affect its expression in MiaPaCa-2 cells.
MYC phosphorylation on Thr58, possibly by GSK-3, is destabilizing while its phosphorylation on Ser62, possibly by ERK, is stabilizing (Sears et al., 2000) . As a possible mechanism for the synergy between PI 3-kinase and Ras, it is supported by our data because, in addition to LY294002, an MEK inhibitor (PD098059) also blocked MYC expression. While GSK-3 and MEK might regulate MYC at a post-translational step, NF-kB and MMAC/PTEN have recently been implicated in its transcriptional regulation (Ghosh et al., 1999; Grumont et al., 2002) . Our data do not, however, support such a role for NF-kB in pancreatic cancer cells.
We show that PI 3-kinase is essential for the proliferation of pancreatic cancer cells consistent with previous studies (Perugini et al., 2000; Bondar et al., 2002; Yao et al., 2002) . The possibility that blocking it might have induced cell cycle arrest in our study is strongly supported by a report that showed BxPC-3 cells to have accumulated in G1 phase under similar conditions (Perugini et al., 2000) . In addition, we employed a dominant-negative mutant and a peptide antagonist to demonstrate that MYC and NF-kB are likely to mediate some of the effects of PI 3-kinase on the proliferation of pancreatic cancer cells.
In summary, we have provided evidence that the PI 3-kinase pathway is constitutively activated in pancreatic cancer, in part, through reduced MMAC/PTEN expression, that it targets the transcription factors NFkB and MYC, and that these two targets might be essential for its central role in the growth and survival of pancreatic cancer cells.
Materials and methods

Materials
AsPC-1, Panc-1, Capan-1, MiaPaCa-2 and BxPC-3 cell lines were obtained from the American Type Culture Collection (ATCC) and cultured as recommended by them. Panc-3 and Panc-28 were kindly provided by Drs Paul Chiao and Keping Xie (MD Anderson Cancer Center) and were maintained under standard culture conditions in DMEM or RPMI-1640 supplemented with 10% fetal bovine serum. Antibodies were obtained either from Santa Cruz Biotechnology (MMAC/ PTEN, p85 PI3K, Akt1/2, GSK-3, p65/NF-kB, c-Src, EGF-R, cyclin D1, p27 Kip1 , c-Myc, Sp-1, TGFb-R, phospho-ERK, actin, p110g-PI3K and IkBa), Cell Signaling Technology (phospho-Akt, phospho-GSK-3 and phospho-MYC) or Chemicon International (anti-RelA/NF-kB activated form). LY294002, PD98059, MG-132 and the NF-kB peptides (SN50 and control SN50M) were obtained from Biomol Research Laboratories Inc. and rapamycin was from Calbiochem. Phosphatidylinositol was purchased from Sigma.
PI 3-kinase assays
Cells were seeded in 60-mm culture dishes overnight, serumstarved for 24 h, and then harvested. Whole-cell lysates were prepared and used for immunoprecipitation with either PY20 (antiphosphotyrosine) or anti-p85 PI 3-kinase antibodies as described previously (Reddy et al., 1997) . Immune complexes were assayed for PI 3-kinase activity with phosphatidylinositol as substrate, and the labeled [ 32 P]phosphatidylinositol 3-phosphate (PIP) was resolved by thin-layer chromatography (Reddy et al., 1997) .
Immunoblotting
Cells were washed with ice-cold phosphate-buffered saline, and whole-cell extracts were prepared as described previously (Koul et al., 2001) . Lysates were clarified by centrifugation, and proteins were resolved by SDS-PAGE. Following protein transfer, nitrocellulose membranes were probed with various antibodies, and specific bands were detected by ECL (Amersham-Pharmacia Biotech).
Viral infections
Panc-28 or AsPC-1 cells were plated on 100-mm dishes, and after 18 h they were mock-infected or infected with a recombinant adenovirus containing MMAC/PTEN (performed at various MOIs; only 25 MOI shown) as described previously (Davies et al., 1998) . The medium was replaced 24 h after infection with fresh media with or without serum, and the cells were cultured for an additional 16 h. Cells were then harvested, and whole-cell lysates were prepared for immunoblotting analysis. Live cells were counted at various times using a hemocytometer.
Immunohistochemistry
Paraffin sections of residual surgical tissues were obtained from 17 patients with ductal pancreatic adenocarcinoma at our institution. These sections were heated at 651C overnight, deparaffinized in xylene and rehydrated in graded alcohol. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide in methanol for 20 min. Sections were then blocked with 3% BSA and normal horse serum at 371C for 30 min, and then overnight with MMAC/PTEN (A2B1) antibody at 41C in a humidified chamber, and finally with a biotinylated secondary antibody for 30 min at 371C. The antibody complex was detected by avidin-biotin-peroxidase complex solution and visualized by 3,3 0 -diaminobenzidine (Zymed Laboratories Inc.). Sections were counterstained with hematoxylin for 5 min and mounted with Eukit (Calibrated Instrument). Immunostaining was observed under a light microscope, and a semiquantitative score for intensity was given to the different samples: strong, moderate, weak or absent, relative to the staining observed for smooth muscle cells in blood vascular wall and in the intestinal wall. Three samples from each MMAC/PTEN expression group (strong, moderate/weak or absent) were then analysed similarly for activated Akt (phospho-Ser473, immunohistochemistryspecific antibody) and activated p65RelA/NF-kB (Wang et al., 1999) .
Methylation-specific PCR
Genomic DNA was isolated from various pancreatic cancer cell lines using the QIAamp Tissue kit (Qiagen). After modification with sodium bisulfite and purification (Wizard DNA Clean-Up kit, Promega), the DNA was employed for PCR reactions with primer sets specific for the methylated or unmethylated MMAC/PTEN promoter as described previously (Salvesen et al., 2001) . The amplification products (methylated and unmethylated) were then mixed, resolved on a 6% polyacrylamide gel and visualized by UV transillumination after ethidium bromide staining. The positive methylation control (206 bp) was generated by treating Panc-1 genomic DNA with an excess of SssI methyltransferase (New England Biolabs) followed by treatment with sodium bisulfite. The negative control (162 bp) was generated by using sodium bisulfite-modified genomic DNA from MiaPaCa-2 cells with the unmethylated primer set.
Reporter assays
Cells were plated in 12-well tissue culture plates and transfected the following day with an (NF-kB) 4 /luciferase reporter or a MYC-responsive M4/luciferase reporter (James and Eisenman, 2002) , a control reporter (pCMV-LacZ), and either an IkB expression plasmid, mutant Akt (Akt-AAA), a constitutively active form of Akt (gag-Akt), Pten, or the dominant-negative mutant of p85a (p85DN) or p110a (p110KR), using the Lipofectamine Plus reagent (Invitrogen) according to the manufacturer's protocol. After 24 h, cells were lysed and assayed for luciferase activity as described elsewhere (Koul et al., 2001) . All values were normalized to bgalactosidase activity determined with the Galacto-Light Plus kit (Tropix).
Stable expression of Mad-Myc in the BxPC-3 cell line
BxPC-3 cells were grown in RPMI-1640 containing 10% FCS, 1000 U/ml penicillin-streptomycin and 2 mM glutamine and transfected with the empty pRc/CMV vector or with the pRc/ CMV-Mad-Myc plasmid using the FuGene reagent (Roche). After 24 h, transfected cells were incubated with 400 mg/ml of G418. Drug-resistant colonies were expanded to generate clonal cell lines.
Growth assays
BxPC-3 cells were seeded overnight in 96-well plates (5 Â 10 3 cells/well) and then cultured in fresh serum-containing medium in the presence or absence of inhibitors (PI 3-kinase inhibitor LY294002 or MEK inhibitor PD98059). Proliferation was estimated by determining the absorbance at 540 nm (crystal violet staining) in a Packard plate reader. Each data point was obtained in triplicate. Control BxPC-3 cells (empty vector) or those stably expressing Mad-Myc were plated in 60 mm culture dishes (1 Â 10 5 cells) to determine the role of MYC in proliferation. After 16 h, the medium was removed and replaced with fresh serum-containing medium. The cells were then cultured for various times following which they were trypsinized and counted. To investigate the role of NF-kB, parental BxPC-3 cells were seeded in 96-well culture plates overnight and incubated the next morning with or without 25 mg/ml control (SN50M) or test (SN50) peptide antagonists of NF-kB nuclear translocation. Cells were then stained with crystal violet and the absorbance at 540 nm was determined.
